HAIFA, Israel, October 26 /PRNewswire-FirstCall/ -- Cardio Vascular
Medical Device Corp. (OTC: CVSL), a leading developer of advanced
cardiovascular surgery technology, today released a brief shareholders update.
Cardio Vascular Medical Device holds a US patent for an innovative
next-generation "steerable guidewire" applicable for all angioplasty (PCTA)
procedures. The guidewire has a unique opportunity to become the guidewire of
choice for surgeons throughout the world.
The technology hinges on a bendable tip that improves guidewire
performance, enables faster procedure completion, and provides cost benefits
for patients as well as healthcare providers.
"Cardio Vascular Medical Device has developed a technology that provides
several advantages over the current guidewires being employed in angioplasty
procedures," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp.
"And with well over 7 million angioplasties performed each year, the global
annual potential addressable market in excess of $500 million."
Cardio Vascular Medical Device is working diligently to complete the
development of the guidewire, in preparation for full commercial distribution.
Cardio Vascular Medical Device Corp. plans to keep public shareholders
informed of all upcoming company developments.
Forward-Looking Statements
This letter contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. All forward-looking statements
are inherently uncertain, based on current expectations and assumptions
concerning future events or future performance of Cardio Vascular Medical
Device Corp. and its technologies. In evaluating such statements, prospective
investors should review carefully various risks and uncertainties identified
in this release, as actual results may differ materially from those indicated
in the forward-looking statements. Cardio Vascular Medical Device Corp.
public filings may be viewed at http://www.sec.gov.
Contact: Alex Traiman, Media Relations, +1-646-863-9729;
Asher Zwebner, +972-54-464-6363, asher@fxmng.com
SOURCE Cardio Vascular Medical Device Corp.
Copyright (2009) PR Newswire. All Rights Reserved.